Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant KPC-2 Producing- Klebsiella pneumoniae Carrying the VEB-25 Gene

• DOI: 10.20944/preprints202306.1769.v1
• Publication Date: 2023-06-27T00:52:11Z
• Authors: Charalampos Zarras; Elias Iosifidis; Maria Simitsopoulou; Styliani Pappa; Angeliki Kontou; Emmanuel Roilides; Anna Papa
• Keywords: Ceftazidime/avibactam

Buckground: Although ceftazidime/avibactam (CAZ/AVI) has become important option for treating adults and children, no recommendations exist neonates. We report a neonatal sepsis case due to CAZ/AVI-resistant KPC-2 producing-Klebsiella pneumoniae carrying blaVEB-25 the use of customized active surveillance program in conjunction infection control measures. Methods: The index was an extremely premature neonate hospitalized 110 days that had been previously treated with multiple antibiotics. Customized molecular implemented at hospital level enhanced measures were taken early recognition prevention outbreak. Detection identification performed by next-generation sequencing. Results: That first bloodstream caused KPC producing K. resistant CAZ/AVI without presence metalo-β-lactamase multiplex PCR platform neonate. All 36 additional patients tested (12 same NICU 24 from other departments) carried wild-type blaVEB-1 but they did not harbor blaVEB-25. Conclusion: emergence VEB-25 is signal horizontal transfer plasmids facilities it greatest concern maintaining sharp vigilance novel resistance mechanisms. Molecular diagnostics can guide appropriate antimicrobial therapy implementation against resistance.